BRIEF published on 05/07/2026 at 08:05, 3 days 5 hours ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 3 days 5 hours ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 3 days 5 hours ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 1 month 10 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 1 month 10 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 1 month 10 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 1 month 22 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
BRIEF published on 03/19/2026 at 10:19, 1 month 22 days ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
PRESS RELEASE published on 03/19/2026 at 10:14, 1 month 22 days ago Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026 Pentixapharm Holding AG to release 2025 financial report on March 26, 2026. CEO and CBO to discuss fiscal year results and strategic priorities in conference call Conference Call Strategic Priorities Clinical Trials Pentixapharm Holding AG 2025 Financial Report
BRIEF published on 02/25/2026 at 08:05, 2 months 13 days ago Pentixapharm Advances CXCR4-Based Hemato-Oncology Program with FDA Approval FDA Approval Hemato-oncology CXCR4-targeted Radiotheranostic Stem Cell Transplant
Published on 05/09/2026 at 01:30, 1 day 12 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 13 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 11:45, 1 hour 45 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 18 hours 25 minutes ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 16 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 18 hours ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 18 hours ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 2 days 18 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 18 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 18 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 18 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 18 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
